Please ensure Javascript is enabled for purposes of website accessibility

3 Dividend Stocks I'd Buy Right Now

By Keith Speights – Apr 26, 2020 at 7:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These stocks offer high dividend yields and solid businesses.

More than 4,000 stocks that trade on U.S. stock exchanges pay dividends. Not all of them necessarily pay mouthwatering dividends, though. And many of them aren't ones that you'd want to buy.

However, there are some dividend stocks that I'd buy right now without hesitation. Here's why AbbVie (ABBV -5.96%), Brookfield Infrastructure Partners (BIP 0.56%), and Brookfield Renewable Partners (BEP 1.16%) are at the top of my list.

Piece of paper with dividends printed on it on top of $100 bills fanned out

Image source: Getty Images.

1. AbbVie

How does a dividend yield of 5.8% sound to you? That's what AbbVie currently offers. Even better, the big pharmaceutical company boasts an impressive track record of dividend hikes -- 47 consecutive years and counting.

I'd argue that AbbVie also qualifies as a bona fide bargain right now. The stock is still down by a double-digit percentage from its highs earlier this year due to the market sell-off resulting from the COVID-19 outbreak. But the drugmaker's business shouldn't be terribly impacted by the pandemic. Its shares trade at well under nine times expected earnings. That's dirt cheap.

One reason why AbbVie is priced so low is that it faces biosimilar competition for its top-selling drug, Humira, in Europe with rivals scheduled to enter the U.S. market in 2023. However, there's a bigger picture for AbbVie that I think some are missing.

The company has already launched two new immunology drugs, Rinvoq and Skyrizi, that will take the baton from Humira and go a long way toward offsetting sales declines for the blockbuster drug. AbbVie also has several other drugs that will help, notably including cancer drugs Imbruvica and Venclexta. In addition, the company should close on its acquisition of Allergan this year, a deal that will make it less dependent on Humira. 

AbbVie might not be a tremendous growth story for now, but it's valued attractively and has a juicy dividend. That's enough to make it a top stock to consider for income-seeking investors.

2. Brookfield Infrastructure Partners

Brookfield Infrastructure Partners' distribution (the equivalent to a dividend for a limited partnership) currently yields close to 5.7%. The company hasn't been in business long enough to claim a streak of dividend increases like AbbVie has. However, Brookfield Infrastructure has nearly tripled its distribution payout over the last 10 years, which is a remarkable achievement.

But as juicy as Brookfield Infrastructure's distribution is, there's a lot more to like about the stock. For one thing, the company has a stable business model. Around 95% of Brookfield Infrastructure's cash flow is either regulated or contracted. That means the company can count on money coming in the door month in and month out.

Its diversification adds to the stability. Brookfield Infrastructure owns infrastructure assets across multiple sectors -- data, energy, transport, and utilities. Less than one-third of the company's total cash flow comes from a single sector. It's also diversified geographically, with no more than 30% of cash flow generated in a single region.

As an added bonus, Brookfield Infrastructure has solid growth prospects. The company expects to increase funds from operations (FFO) by between 6% and 9% over the long run. That level of growth combined with its attractive distribution put the infrastructure stock in the top tier of dividend stocks, in my view.

3. Brookfield Renewable Partners

It's not a mere coincidence that Brookfield Renewable Partners has a name very similar to Brookfield Infrastructure Partners. The general partner of both companies is a subsidiary of Brookfield Asset Management. Like its infrastructure-focused sibling, Brookfield Renewable offers a great distribution with a current yield of 4.9%. 

With uncertainties in the economy as a result of the COVID-19 pandemic, I like that Brookfield Renewable has maintained the lowest-risk balance sheet in the renewable energy sector. The company has plenty of liquidity to survive and thrive during an economic downturn.

I also like Brookfield Renewable's relative diversification. The company has significant operations in hydroelectric, solar, and wind electricity generation as well as a sizable storage capacity. It also operates globally, with renewable energy facilities in Asia, Europe, North America, and South America.

But what I most like about this stock is its potential to deliver market-beating total returns. Brookfield Renewable targets a total return of 12% to 15%, with around 5% coming from its distribution yield and another 10% coming from cash flow growth. With the use of renewable energy sources almost certain to increase dramatically over the next decade and beyond, Brookfield Renewable is probably one of the most future-proof stocks on the market. 

Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Brookfield Renewable Partners L.P. The Motley Fool owns shares of and recommends Brookfield Asset Management. The Motley Fool recommends Brookfield Infrastructure Partners. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Brookfield Infrastructure Partners L.P. Stock Quote
Brookfield Infrastructure Partners L.P.
BIP
$35.90 (0.56%) $0.20
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$134.21 (-5.96%) $-8.51
Brookfield Renewable Partners L.P. Stock Quote
Brookfield Renewable Partners L.P.
BEP
$31.30 (1.16%) $0.36
Allergan plc Stock Quote
Allergan plc
AGN
Brookfield Asset Management Inc. Stock Quote
Brookfield Asset Management Inc.
BAM
$40.89 (0.42%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.